Nanobiotix is trading 5.88% lower at $26.26, with no clear announcement explaining the October 2 move. - The company announced first data from a Phase 1 esophageal cancer study on October 2; available reporting does not link it to the decline. - Shares fell 10.46% on October 1 after a CFO transition announcement, but that earlier move does not establish the cause of the current decline. - Broader U.S. markets are higher; no volume data was available.